Palvella Therapeutics (PVLA) announced the launch of “BEYOND mLM,” a new disease state awareness campaign and website designed to educate patients, caregivers, and healthcare professionals about microcystic lymphatic malformations. “We are delighted to see Palvella bring together experts and organizations who share a commitment for improving the lives of patients with microcystic lymphatic malformations,” said Dr. Michael Kelly, pediatric hematologist-oncologist at the Cleveland Clinic’s Vascular Anomalies Program and Executive Director of the LGDA. “Patients with microcystic lymphatic malformations often lack access to educational materials written in a way that is accessible and practical. This effort will help provide valuable resources not only for patients and caregivers, but also for healthcare providers seeking to deepen their understanding of this complex condition.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics price target raised to $220 from $200 at Clear Street
- Palvella Therapeutics price target raised to $220 from $200 at Chardan
- Palvella Therapeutics Announces Underwritten Common Stock Offering
- Palvella Therapeutics 1.6M share Secondary priced at $125.00
- Palvella Therapeutics price target raised to $250 from $205 at Mizuho
